Basal forebrain neurons and memory: a biochemical, histological, and behavioral study of differential vulnerability to ibotenate and quisqualate.
The differential vulnerability of basal forebrain cells to ibotenate (IBO) or quisqualate (QUIS) was investigated in rats. IBO was also coinjected with cystine (CYS) or zinc (Zn). Cortical choline acetyltransferase (ChAT) and glutamate decarboxylase (GAD) activity, neurotensin receptors, and high-affinity choline uptake sites were quantified in conjunction with radioimmunoassays for neurotensin, substance P, and somatostatin; immunocytochemistry for neurotensin-, somatostatin-, Leu-enkephalin-, and ChAT-positive cells; and in situ hybridization histochemistry of somatostatin, substance P, and enkephalin mRNAs. Compared with the performance of controls, continuous alternation performance in a T maze of IBO+Zn or IBO+CYS rats was better than that of IBO rats, whereas the performance of QUIS rats was unimpaired. Of those neurotransmitter systems examined, only ChAT-immunoreactive cells were vulnerable to IBO or QUIS. However, cholinergic cell loss did not correlate with impaired performance.
D000818:Animals; D001288:Attention / Q000187:drug effects* / Q000502:physiology; D001931:Brain Mapping; D002540:Cerebral Cortex / Q000187:drug effects / Q000502:physiology; D002795:Choline O-Acetyltransferase / Q000502:physiology; D002799:Cholinergic Fibers / Q000187:drug effects / Q000502:physiology; D003553:Cystine / Q000494:pharmacology; D004193:Discrimination Learning / Q000187:drug effects* / Q000502:physiology; D004743:Enkephalin, Leucine / Q000502:physiology; D005917:Globus Pallidus / Q000187:drug effects / Q000502:physiology; D005968:Glutamate Decarboxylase / Q000502:physiology; D007051:Ibotenic Acid / Q000494:pharmacology*; D008297:Male; D011939:Mental Recall / Q000187:drug effects* / Q000502:physiology; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D009479:Neuropeptides / Q000502:physiology*; D009496:Neurotensin / Q000502:physiology; D009949:Orientation / Q000187:drug effects* / Q000502:physiology; D016548:Prosencephalon / Q000187:drug effects* / Q000502:physiology; D016318:Quisqualic Acid / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000502:physiology; D013004:Somatostatin / Q000502:physiology; D013373:Substance P / Q000502:physiology; D013377:Substantia Innominata / Q000187:drug effects / Q000502:physiology; D015032:Zinc / Q000494:pharmacology
D009479:Neuropeptides; D011950:Receptors, Cholinergic; D018028:Receptors, Neurotensin; D017981:Receptors, Neurotransmitter; D007051:Ibotenic Acid; D013373:Substance P; D009496:Neurotensin; D003553:Cystine; D013004:Somatostatin; D004743:Enkephalin, Leucine; D016318:Quisqualic Acid; D002795:Choline O-Acetyltransferase; D005968:Glutamate Decarboxylase; D015032:Zinc